These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 23263559)

  • 41. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation.
    Imanishi Y; Matsui K; Ishida K; Ito S; Matsuura K; Deguchi T; Itoh Y
    Arzneimittelforschung; 2011; 61(3):191-6. PubMed ID: 21528645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient.
    Merli M; Di Menna S; Giusto M; Giannelli V; Lucidi C; Loria I; Ginanni Corradini S; Mennini G; Rossi M
    Transplant Proc; 2010 May; 42(4):1322-4. PubMed ID: 20534292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients.
    Wu SW; Tsai HC; Tsai PY; Hung TW; Chang HR; Lian JD
    Swiss Med Wkly; 2013; 143():w13850. PubMed ID: 23986367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge.
    Jannot M; Masson I; Alamartine E; Mariat C
    Ann Transplant; 2014 Jul; 19():320-4. PubMed ID: 24999809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen.
    Eberlin M; Otto G; Krämer I
    Transplant Proc; 2013; 45(6):2314-20. PubMed ID: 23726723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients.
    Tinti F; Meçule A; Poli L; Bachetoni A; Umbro I; Brunini F; Barile M; Nofroni I; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 Dec; 42(10):4047-8. PubMed ID: 21168623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conversion From Twice-Daily to Once-Daily Tacrolimus Among Egyptian Living-Donor Kidney Allograft Recipients: A Single-Center Experience.
    Bakr MA; Nagib AM; Abbas MH; Donia AF
    Exp Clin Transplant; 2019 Oct; 17(5):594-598. PubMed ID: 31050617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial.
    Wlodarczyk Z; Ostrowski M; Mourad M; Krämer BK; Abramowicz D; Oppenheimer F; Miller D; Dickinson J; Undre N
    Ther Drug Monit; 2012 Apr; 34(2):143-7. PubMed ID: 22406656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
    Wente MN; Sauer P; Mehrabi A; Weitz J; Büchler MW; Schmidt J; Schemmer P
    Clin Transplant; 2006; 20 Suppl 17():80-4. PubMed ID: 17100706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus.
    Kurnatowska I; Krawczyk J; Oleksik T; Nowicki M
    Transplant Proc; 2011 Oct; 43(8):2954-6. PubMed ID: 21996199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan.
    Takahashi K; Abe R; Usuki S; So M
    Transplant Proc; 2014; 46(2):406-10. PubMed ID: 24655975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 59. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan.
    Uemoto S; Abe R; Horike H; So M
    Transplant Proc; 2014 Apr; 46(3):749-53. PubMed ID: 24767340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients.
    Umbro I; Tinti F; Mecule A; Bachetoni A; Poli L; Pignatelli A; Alessandri C; Fiacco F; D'Alessandro M; Di Natale V; Berloco PB; Valesini G; Mitterhofer AP
    Transplant Proc; 2012 Sep; 44(7):1907-9. PubMed ID: 22974867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.